TARA

Protara Therapeutics Inc

TARA, USA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

https://www.protaratx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TARA
stock
TARA

Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA MarketBeat

Read more →
TARA
stock
TARA

Protara Therapeutics announces $75M common stock offering MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$25

Analyst Picks

Strong Buy

5

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

1.82

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.02 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.17 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 73.28% of the total shares of Protara Therapeutics Inc

1.

HHG PLC

(10.6335%)

since

2025/06/30

2.

BlackRock Inc

(5.5567%)

since

2025/06/30

3.

Velan Capital Investment Management LP

(5.5441%)

since

2025/06/30

4.

Blackstone Inc

(4.9496%)

since

2025/06/30

5.

Vanguard Group Inc

(4.6705%)

since

2025/06/30

6.

Catalio Capital Management, LP

(4.2154%)

since

2025/06/30

7.

Integral Health Asset Management, LLC

(3.6286%)

since

2025/06/30

8.

StemPoint Capital LP

(2.9643%)

since

2025/06/30

9.

UBS Group AG

(2.9438%)

since

2025/06/30

10.

RA Capital Management, LLC

(2.6937%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(2.5965%)

since

2025/07/31

12.

Opaleye Management Inc

(2.2161%)

since

2025/06/30

13.

Woodline Partners LP

(2.2074%)

since

2025/06/30

14.

5AM Venture Management, LLC

(2.0735%)

since

2025/06/30

15.

Geode Capital Management, LLC

(1.9297%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(1.6775%)

since

2025/08/31

17.

Millennium Management LLC

(1.4621%)

since

2025/06/30

18.

Baker Bros Advisors LP

(1.3914%)

since

2025/06/30

19.

Citadel Advisors Llc

(1.0692%)

since

2025/06/30

20.

Adage Capital Partners Gp LLC

(1.0368%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9415%)

since

2025/07/31

22.

Marshall Wace Asset Management Ltd

(0.9396%)

since

2025/06/30

23.

SUPERSTRING CAPITAL MANAGEMENT LP

(0.9331%)

since

2025/06/30

24.

Fidelity Small Cap Index

(0.8329%)

since

2025/06/30

25.

iShares Russell 2000 Value ETF

(0.7261%)

since

2025/08/31

26.

Fidelity Extended Market Index

(0.4742%)

since

2025/07/31

27.

CREF Stock R3

(0.4671%)

since

2025/07/31

28.

Vanguard Russell 2000 ETF

(0.4026%)

since

2025/07/31

29.

State St Russell Sm Cap® Indx SL Cl I

(0.2931%)

since

2025/08/31

30.

Schwab Small Cap Index

(0.2094%)

since

2025/07/31

31.

NT R2000 Index Fund - NL

(0.2024%)

since

2025/06/30

32.

Vifag 2002 SICAV

(0.1944%)

since

2025/07/31

33.

iShares Micro-Cap ETF

(0.1925%)

since

2025/08/31

34.

NT R2000 Index Fund - DC - NL - 3

(0.1614%)

since

2025/06/30

35.

Fidelity Total Market Index

(0.1539%)

since

2025/07/31

36.

Avantis US Small Cap Equity ETF

(0.1511%)

since

2025/08/30

37.

iShares Russell 2000 Small-Cap Idx Instl

(0.145%)

since

2025/07/31

38.

Extended Equity Market Fund K

(0.1367%)

since

2025/06/30

39.

Bridgeway Ultra-Small Company Market

(0.1361%)

since

2025/06/30

40.

Fidelity Series Total Market Index

(0.1284%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.31

EPS Estimate

-0.3775

EPS Difference

0.0675

Surprise Percent

17.8808%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.